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Abstract
As evidence accumulates on the use of genomic tests and other health-related applications of 
genomic technologies, decision makers may increasingly seek support in identifying which 
applications have sufficiently robust evidence to suggest they might be considered for action. As 
an interim working process to provide such support, we developed a horizon-scanning method that 
assigns genomic applications to tiers defined by availability of synthesized evidence. We illustrate 
an application of the method to pharmacogenomics tests.
BACKGROUND
Since the Human Genome Project concluded a decade ago, the landscape of genomic 
medicine has become increasingly complex, burgeoning with applications for clinical or 
personal use.1–3 The state of evidence surrounding implementation of genetic tests, 
however, has been described by some as a dilemma.4 Indeed, oftentimes no guidelines exist 
that aid in decision making on the implementation of genomics-based technologies. When 
guidelines do exist, they often frustrate clinical and other audiences due to findings of 
insufficient evidence on their use.5 Furthermore, not all guideline development groups use 
the same methods to arrive at recommendations; therefore, if different groups were to 
address the same topic, they might come to dissimilar conclusions. As a result of this 
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variability in methods, conclusions on the same topic may differ. Potential discrepancies 
may be resolved by careful comparison of guidelines; however, it would be useful to have a 
systematic approach that allows decision makers a horizon scanning of synthesized evidence 
sources relevant to the use of a particular genetic test.
The Office of Public Health Genomics (OPHG) at the Centers for Disease Control and 
Prevention (CDC), in collaboration with the National Cancer Institute Epidemiology and 
Genomics Research Program, recently modified an existing classification system6 and 
created an evolving table of genomic tests sorted by level of evidence.7 The table presents 
an evidence-ordered classification of “genomic applications” (defined here as the use of 
gene-based tests in specific clinical scenarios, or use of genome-related information, such as 
knowledge about a specific variant, to aid in clinical decision making in specific clinical 
scenarios), rather than a classification of laboratory assays themselves. We have previously 
described classification of cancer genomic tests (http://blogs.cdc.gov/genomics/2012/08/23/
evidence-matters-in-genomic-medicine-round-2/) and family history applications (http://
blogs.cdc.gov/genomics/2012/09/27/evidence-matters-in-genomic-medicine-round-3/) into 
the three-tiered system in blogs that are available on the OPHG website. Here, we describe 
the methodological underpinnings of this system and use the example of pharmacogenomics 
tests to illustrate how this system can be used to classify genomic applications.
We supplement our three-tier classification system with a color scheme that emulates the 
workings of a traffic signal to emphasize that the evidence under consideration relates to 
whether or not the application is likely to be considered for action. Our classification scheme 
stratifies applications into three categories:
• Tier 1/Green genomic applications have a base of synthesized evidence that 
supports implementation in practice.
• Tier 2/Yellow genomic applications have synthesized evidence that is insufficient 
to support their implementation in routine practice. Nevertheless, the evidence may 
be useful for informing selective use strategies (such as in clinical trials) through 
individual clinical, or public health policy, decision making.
• Tier 3/Red applications either (i) have synthesized evidence that supports 
recommendations against or discourages use, or (ii) no relevant synthesized 
evidence is available.
We have developed a simple classification method to aid in the tier assignment process. 
When coupled with the aforementioned online table, the method may be viewed as the basis 
of an interim, working process intended to inform critical evaluation of genomic 
applications by end users until the evidence base becomes more robust and more 
comprehensive resources (e.g., ClinGen, funded by the National Institutes of Health, which 
aims to catalog medically relevant human gene variants) become available. It is intended to 
serve as a launching point for health researchers and as a guideline for developers, policy 
makers, and others looking for a basic overview of the amount of synthesized evidence 
relevant to particular genes or tests. It offers a first, quick look at how much synthesized 
evidence is available for use in decision making, as well as a subjective overview of what 
that evidence has to say about implementation. We have designed the approach primarily to 
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benefit an audience of clinicians and public health policy makers interested in implementing 
specific genomic applications. This horizon-scanning method can also point quickly to 
existing evidence gaps and/or lack of guidelines and recommendations. Our approach is not, 
however, intended to supplant clinical decision making. The approach does not prescribe 
how evidence synthesis or guidelines can be arrived at. The following sections describe the 
method and illustrate its application through the lens of pharmacogenomic applications. In 
tandem, we highlight salient characteristics of the processes currently used for guideline 
development and evidence synthesis by the many groups working to address the field of 
genomic medicine.
DESCRIPTION OF CLASSIFICATION METHOD
Synthesized evidence on genomic applications can be considered the input for our method, 
and the output is an evidence-based classification of applications. Thus, the process will not 
yield conclusions such as “testing for gene X is a Tier 2/Yellow application.” Instead, 
conclusions are of the form “testing for gene X to predict susceptibility to disease Y, in 
people with characteristics Z1,2,…n is a Tier 2/Yellow application.” The classification 
method (Figure 1) incorporates evidence derived from US Food and Drug Administration 
(FDA) labeling information, Centers for Medicare & Medicaid Services (CMS) coverage 
decisions, clinical practice guidelines (CPGs), and systematic reviews (SRs). Classification 
centers on (i) intent of guidance (e.g., to inform decisions on use of a test vs. decisions on 
use of the results of a test) and (ii) applicability of sources, rather than methodological rigor 
in review or guideline development processes.
Guidelines reporting their basis to be an SR are categorized by our process as evidence 
based, regardless of whether the SR has been published or is publicly available. If a review 
process appears to have involved prespecified search terms regarding key questions, we 
consider it to be an SR, even if the authors did not label it as such. Examples of some major 
sources of evidence, and how they could be classified for use in our method, are provided in 
Table 1. We have not included guidelines and reviews that are primarily aimed at facilitating 
laboratory practice.
DEFINING GENOMIC APPLICATIONS
The genomic application to be classified must be clearly described before relevant evidence 
can be identified. Our definition process is based on methods for topic development used by 
the Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working 
Group, and we echo its view-point that “. . . clear definition of the clinical scenario is of 
major importance, as the performance characteristics of a given test may vary depending on 
the intended use of the test, including the clinical setting (e.g., primary care, specialty 
settings), how the test will be applied (e.g., diagnosis or screening), and who will be tested 
(e.g., general population or selected high risk individuals).”8 Thus, inspired by the EGAPP 
and the precedent ACCE (analytic validity, clinical utility, ethical legal and social 
implications) model process,9 we consider the disorder, the test, and the context in which the 
test is used (the clinical scenario) in describing specific genomic applications.8
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Once the genomic application has been specified, the first step toward classification is to 
identify the synthesized evidence to be considered. The CDC OPHG has previously created 
a broad-based horizon-scanning process to track the introduction of genomic applications 
into clinical research and practice,10 and we assess the findings for sources of synthesized 
evidence on genomic applications. We use regular, weekly PubMed searches to identify 
relevant literature, such as published SRs, and Google Alerts to probe key areas of the gray 
literature. We also regularly check the websites of major guideline development groups, 
such as the US Preventive Services Task Force,11 the American College of Medical 
Genetics and Genomics (ACMG),12 and many others, for new or updated guidelines. 
General resources such as the National Guideline Clearinghouse,13 National Institutes of 
Health Genetic Testing Registry,14 PharmGKB,15 and PubMed16 are also highly effective 
tools in searching for evidence. PharmGKB also includes criteria for levels of evidence for 
variant-drug combinations, and although these criteria differ from those presented here, the 
results are nonetheless useful in determining what type of evidence is available to support 
use of pharmacogenomics tests. The information we find on newly introduced tests and 
guidelines is searchable online at the Genomic Applications in Practice and Prevention 
Knowledge Base (GAPP KB) (http://www.hugenavigator.net/GAPPKB/home.do), and any 
information identified from synthesized evidence sources is used to update the table of 
genomic tests by level of evidence7 on an as-needed basis.
Identifying relevant FDA-approved drug label information is relatively simple using the 
FDA Table of Pharmacogenomic Biomarkers in Drug Labels,17 which points directly to the 
appropriate label sections. However, this table may not necessarily be a complete listing, 
e.g., cytochrome P450 (CYP) 2D6 inclusion in the label for sertraline hydrochloride is not 
found in the current FDA table; therefore, additional sources may increase yield. The FDA 
510(k) premarket notification database is a good source to search for approved tests that 
may be required in FDA labeling18; however, search fields require some previous 
knowledge of the device, applicant, or other specialized information. CMS coverage 
decisions are also relatively easy to locate in the Medicare Coverage Database19; however, 
the user must devise appropriate search terms to retrieve relevant information.
APPLYING THE CLASSIFICATION METHOD
After synthesized evidence for a genomic application has been identified and collected, the 
list of criteria (Figure 1) is simply read from top to bottom. Four sources of evidence are 
considered: (i) FDA drug label information, including companion diagnostic designation; 
(ii) CMS national coverage determination, local coverage determination, and coverage with 
evidence development (CED) determination; (iii) CPGs; and (iv) SRs. Examples of some 
major sources of evidence, and how they could be considered using our method, are 
provided in Table 1. If any of the evidence for the test conforms to one or more of the 
bulleted descriptions in the Tier 1/Green category, then the process is complete, and the 
assignment is Tier 1/Green. If none of the Tier 1/Green descriptions apply, then the process 
is repeated for the Tier 2/Yellow category and then for the Tier 3/Red category, if necessary. 
In general, if more than one bulleted description can be applied, then the higher tier/category 
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is assigned. An exception occurs when the Tier 2/Yellow description “FDA label mentions 
biomarker” applies; in this case, reassignment to the lower category remains possible if any 
Tier 3/Red descriptions also apply.
Criteria for Tier 1/Green
Tier 1/Green genomic applications have been deemed ready to implement in clinical 
practice. There are three possible paths leading to the Green category: (i) an FDA-approved 
drug label requires the use of a genomic test to inform the choice or dose of a drug, or (ii) 
CMS covers (national coverage determination or local coverage determination) use of a 
genomic test, or (iii) there is at least one CPG, based on findings of an SR, that supports use 
of a genomic test.
Determining whether an FDA label requires a genomic application, rather than simply 
recommending a test or mentioning a biomarker, is not always as straightforward as it might 
seem, and specific examples are presented in the next section. We have chosen to use 
Agarwal’s proposed definition of companion diagnostics as “. . . any type of diagnostic test 
that must be administered before a drug can be prescribed, not just genetic or protein arrays. 
For inclusion, the diagnostic test must be part of the FDA approved label for the drug and 
language in the label must require testing and provide information on the required outcomes 
of the testing. Testing also must be mandated for all potential patients or at least one patient 
segment (e.g. women of child-bearing age, children). Drugs with labels that only 
recommended testing are not included nor are drugs in which the testing is at the discretion 
of an individual physician.”20 Therefore, presence of a biomarker in the FDA Table of 
Pharmacogenomic Biomarkers in Drug Labels17 is not in itself sufficient for Tier 1/ Green 
classification because the biomarker may only be mentioned in the label with no 
requirement for testing, as described above. In many cases, pharmacogenomic information 
in drug labels may not refer to genetic testing but can be an aid to clinical decision making 
(e.g., in warning of potential drug interactions due to common metabolic pathways) as well 
as the basis of a genomic application as we have defined the term above. We have 
considered these labels to refer to genomic applications only when relevant information on a 
specific genetic variant is provided; otherwise, we have excluded them from classification. 
Moreover, it is necessary to read the entire label carefully to determine whether or not a 
genomic application is required. On the other hand, no additional review is needed for 
applications listed in the FDA Table of Companion Diagnostic Devices: In Vitro and 
Imaging Tools21; because the FDA requires their use, they are classified as Tier 1/Green.
The process of determining whether a drug label actually requires testing is averted when 
Tier 1/Green can be assigned based on CMS coverage or based on a CPG with SR. Caveats 
are that with CMS decisions, although a national coverage determination or local coverage 
determination may qualify for Tier 1/Green, CED does not. If a CPG is the basis of Tier 1/
Green assignment, then the CPG must be based on the findings of an SR covering the same 
clinical scenario.
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Criteria for Tier 2/Yellow
The Tier 2/Yellow category designates genomic applications that may be useful in the 
context of informed clinical decision making. As shown in Figure 1, there are seven paths 
leading to the Yellow category. When an FDA label mentions a genetic test but does not 
require it, the genomic application is classified as Tier 2/Yellow; however, if any other 
criteria from Tier 3/Red or Tier 1/Green apply, it is reclassified accordingly. For example, if 
pharmacogenomic information is mentioned in an FDA-approved drug label, but there is no 
requirement for testing or other action, and a CPG recommends against use of the test, then 
the genomic application is classified as Tier 3/Red.
Genomic applications meeting any of the remaining Tier 2/Yellow criteria cannot be 
reclassified downward by our method into Tier 3/Red on the basis of additional conditions. 
Genomic applications covered under CMS CED are considered Tier 2/Yellow because there 
has been a formal decision process leading to restricted coverage with a requirement for data 
collection and the understanding that it will be used to facilitate reexamination of coverage 
in the future.22 Positive recommendations in CPGs that are not based on SRs, such as many 
consensus guidelines, qualify a genomic application for Tier 2/Yellow, as do positive 
findings from an SR that has no associated CPG. Any CPG or SR that determines there is 
insufficient evidence (IE) to support the use of a genomic application, but does not go on to 
discourage use of the test based on findings, is also a qualifier for Tier 2/Yellow. It should 
be noted that some guideline development groups, such as the EGAPP Working Group, 
qualify IE recommendations along lines of encouraging, neutral, or discouraging.8 For CPGs 
from groups that do not make such qualifications, we consider IE recommendations to be 
positive or neutral unless the authors clearly present negative contextual factors that they 
expect would outweigh any potential benefits from testing. Admittedly, the use of different 
language and different rules in stating conclusions among various groups developing SRs 
and CPGs can make the distinction between Tier 2/Yellow and Tier 3/Red a subjective 
interpretation; this may be unavoidable unless more detailed tools are used (see Discussion 
section).
Finally, Tier 2/Yellow contains genomic applications for which a CPG recommends dosage 
adjustment (or other clinical action) based on results of the test, if available, but does not 
address whether or not testing should be done. Guidelines from two groups devoted to 
pharmacogenomic applications, the Clinical Pharmacogenetics Implementation 
Consortium23 and the Royal Dutch Association for the Advancement of Pharmacy’s 
Pharmacogenetics Working Group,24,25 address what to do with the results under the 
assumption that they are available, but not whether testing should be done.26 With the 
plummeting cost of whole-genome sequencing, there is an expectation that the existing 
paradigm of clinical testing for one or several genetic variants at a time will be replaced by 
one in which millions of results will be readily available. Critical questions will be which 
results should be used and how they should be used. Groups such as the American College 
of Medical Genetics and Genomics,27 the EGAPP,28 and others have recently begun to 
grapple with the question of how to deal with incidental findings from whole-genome and 
whole-exome sequencing tests. The novel approaches to pharmacogenomic guideline 
development, pioneered by the Clinical Pharmacogenetics Implementation Consortium and 
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the Pharmacogenetics Working Group, seem to correspond with current thinking on how 
genomic information overload may be managed in the future. Nevertheless, as a basis for 
informed decision making on whether or not to use a test, supplementing these sources with 
evaluations of clinical utility may be helpful.
Criteria for Tier 3/Red
The Tier 3/Red category designates genomic applications that are not suitable for 
implementation in clinical practice because either there is no supporting synthesized 
evidence or there is evidence that potential harms outweigh potential benefits at the current 
time. Instances in which adequate synthesized evidence suggests that a genomic application 
is neither harmful nor helpful would also be considered Tier 3/Red. When there is no 
synthesized evidence, a coherent case can be made for not applying our classification 
method at all, and leaving such genomic applications unassigned until some evidence is 
available. Ultimately, however, this is a value judgment that various users will be able to 
make for themselves. In the way that we have chosen to use the classification method, there 
are five paths leading to the Red category, as shown in Figure 1.
Although more than 100 FDA-approved drug labels include information on 
pharmacogenomic biomarkers,17 we have not found any that specifically caution against use 
of an associated test. This path was retained in our method to address the possibility that this 
type of information could be included in future label revisions. CMS national coverage 
determinations or local coverage determinations that result in noncoverage place a genomic 
application in Tier 3/Red. CMS CED decisions are not considered noncoverage for the 
purposes of our method. CPGs (whether based on an SR or not) and SRs (whether 
associated with a CPG or not) that either find IE and discourage use of a test or find 
adequate evidence to recommend against use of a test are sufficient for Tier 3/Red 
placement. Finally, the lack of any synthesized evidence in the form of sources listed above 
results in Tier 3/Red placement.
SPECIFIC EXAMPLES
This section illustrates the use of our horizon-scanning method with several specific 
examples. The examples have been chosen to (i) demonstrate how the method works and (ii) 
present cases for which classification is difficult and involves greater use of subjective 
judgment. Pharmacogenomic examples are used wherever possible because they are often 
the most challenging in terms of classification. Readers wishing to examine results for all 
the genomic applications that we have classified to date are encouraged to look at the 
evolving online table of Genomic Tests and Family History by Levels of Evidence that is 
maintained and updated periodically on the CDC OPHG website.7
Tier 1/Green example
This example, of KRAS testing in metastatic colorectal cancer, illustrates how placement can 
change with evidence development over time. In 2008, the Blue Cross Blue Shield 
Association Technology Evaluation Center issued a technology assessment29 supporting 
KRAS mutation analysis in patients with metastatic colorectal cancer who are being 
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considered for anti–epidermal growth factor receptor therapy as a means to predict 
nonresponse to treatment with cetuximab or panitumumab. Rigorous technology 
assessments, such as those conducted by the Blue Cross Blue Shield Association 
Technology Evaluation Center are considered as an SR in our method. If our method had 
been developed at that time, this information would have been sufficient for placing KRAS 
testing, with the designated clinical scenario (use in patients with metastatic colorectal 
cancer who are being considered for anti–epidermal growth factor receptor therapy as a 
means to predict nonresponse. . .), into the Tier 2/Yellow category. Subsequently, however, 
CPGs became available in the form of an American Society of Clinical Oncology 
provisional clinical opinion,30 National Comprehensive Cancer Network guidelines, 31 and 
finally, a recommendation statement from the EGAPP Working Group.32 Each of these 
subsequent evidence sources supported testing in the same clinical scenario, and 
consideration of any one of them could warrant placement into Tier 1/Green. The EGAPP 
recommendation was based on pre-existing SRs, including the Blue Cross Blue Shield 
Association Technology Evaluation Center assessment, whereas the processes and sources 
described in the National Comprehensive Cancer Network and American Society of Clinical 
Oncology guidelines were deemed sufficient to consider them based on unpublished SRs. If 
the method were initially applied today, the classification process would be completed based 
on the first criterion because there are FDA-approved products as companion diagnostic 
devices21 for this genomic application, which—by default—means that testing is required in 
the FDA labels for cetuximab and panitumumab.
Tier 2/Yellow examples
This example illustrates a step-by-step approach to categorizing TPMT (thiopurine 
methyltransferase) testing in patients with leukemia before treatment with mercaptopurine to 
inform dosage. Proceeding through the list of criteria from the top down, the first step is to 
determine whether an FDA label requires use of a test to inform choice or dose of a drug. 
The FDA Table of Pharmacogenomic Biomarkers in Drug Labels17 contains an entry 
indicating that TPMT is at least mentioned in the label contents. Following links from the 
table to the latest labeling revision,33 we find that “[h]eterozygous patients with low or 
intermediate TPMT activity accumulate higher concentrations of active thioguanine 
nucleotides than people with normal TPMT activity and are more likely to experience 
mercaptopurine toxicity,” and “TPMT genotyping or phenotyping . . . can identify patients 
who are homozygous deficient or have low or intermediate TPMT activity,” and that 
“[s]ubstantial dose reductions are generally required for homozygous-TPMT deficiency 
patients (two non-functional alleles) to avoid the development of life threatening bone 
marrow suppression.” Although this information could be used for decision making, there is 
no statement that testing is required. The second criterion, CMS coverage, is examined by a 
search of the Medicare Coverage Database19 by document type, selecting “National and 
Local Coverage Documents” and “Geographic Area/Region: All States,” for the keyword 
“TPMT.” No documents are returned from this search; hence, we move on to the last 
criterion for Tier 1/Green placement, a CPG based on an SR that supports testing in this 
clinical scenario. Our horizon-scanning efforts have returned only one CPG,34 along with a 
subsequent update35 from the Clinical Pharmacogenetics Implementation Consortium. The 
original CPG contains recommendations on TPMT-based dosing but does not address 
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whether testing should or should not be done34; therefore, we move to Tier 2/Yellow and 
consider where this information fits. The CPG update does not change the original 
recommendation but provides updated information.35 It is found that the CPG and update 
satisfy the last criterion listed under Tier 2/Yellow, and therefore the classification is 
complete. Once it was determined that Tier 1/Green criteria were not met, the FDA labeling 
information qualified this genomic application for Tier 2/Yellow, but this assignment would 
be conditional on no Tier 3/Red criteria being met.
Another informative example of Tier 2/Yellow placement is the case of CYP2C9 and 
VKORC1 testing in patients before treatment with warfarin to inform dosage. In 2008, the 
American College of Medical Genetics and Genomics published a CPG36 on this topic, 
based on an SR.37 The result was an IE statement, and although testing was not endorsed by 
the guideline developers, they pointed to the need for more studies, 36 so we do not consider 
it a “discouraging” statement. In 2009, the CMS issued a CED to cover this testing in 
clinical studies and under certain conditions.38 In 2011, the Clinical Pharmacogenetics 
Implementation Consortium issued a CPG informing dose adjustment but not use of the 
test.39 The FDA-approved drug label for warfarin includes information on CYP2C9 and 
VKORC1 but does not require that testing be done.40 Furthermore, there is an FDA 510(k)-
approved genotyping assay,41 but no apparent requirement for testing. Each of the items 
mentioned fit neatly into one of the Tier 2/Yellow criteria, and any of these sources on their 
own would warrant placement in Tier 2/Yellow.
Tier 3/Red example
CYP2D6 and CYP2C19 testing to inform dosage of selective serotonin reuptake inhibitor 
antidepressant drugs in adults with major depression is an example of Tier 3/Red 
assignment. Looking at the clinical scenario of using this testing before treatment with 
paroxetine to inform dosage, one finds that the FDA-approved drug label mentions CYP2D6 
but does not require testing. Moreover, the label refers to an entirely different clinical 
scenario, involving CYP2D6 enzyme inhibition, which may result in drug interactions,42 
rather than the testing-based genomic application we initially set out to classify. There is an 
FDA 510(k) substantial equivalence determination for a CYP2D6 genotyping test that is 
“intended to identify a patient’s CYP2D6 genotype . . . [which] may be used as an aid to 
clinicians in determining therapeutic strategy and treatment dose for therapeutics that are 
metabolized by the CYP2D6 gene product.”41 This description could fit the scenario of 
interest in this example, but again, there is no requirement for testing. An evidence review 
has been conducted on this topic by an Agency for Healthcare Research and Quality 
Evidence-Based Practice Center,43,44 and this was the basis for a recommendation statement 
by the EGAPP Working Group in 2007.45 The EGAPP recommendation found IE and 
“discourage[d] use of CYP450 testing for patients beginning SSRI treatment until further 
clinical trials are completed.”45 The FDA labeling information alone would have led to 
classification as Tier 2/Yellow; however, this is an example of conditional classification; the 
IE/discouraging result of a CPG based on an SR supersedes it, and Tier 3/Red classification 
is the result. It is up to users to decide how far to go back temporally for including evidence. 
In this case, the latest labeling revision is relatively recent, whereas the superseding CPG is 
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6 years old. However, in most cases Tier 3/Red assignment is based on the lack of any 
synthesized evidence, making the classification decision straightforward.
DISCUSSION
In beginning to address questions of clinicians, healthcare payers, and patients about 
whether or not to offer a genomic application, cover it, or use it, simple heuristic devices can 
help in gathering, organizing, and understanding existing relevant evidence. Our 
classification method and associated table are primarily designed to answer two questions: 
(i) what are the sources of synthesized evidence on a particular genomic application and (ii) 
what do these sources have to say, in general terms, about whether or not the genomic 
application is ready for implementation. They are not intended to answer the ultimate 
question of whether or not to implement an application; rather, we hope they will help to 
direct decision makers toward genomic applications for which there is some supporting 
synthesized evidence so that more formal decision-making techniques can be focused on the 
most promising areas. For those who wish to base implementation on current sources of 
synthesized evidence, Tier 1/Green and Tier 2/Yellow listings should be of immediate 
assistance in obtaining an overview of which genomic applications are associated with 
existing supportive evidence from CPGs and SRs, as well as with information from the FDA 
and the CMS.
Our method classifies genomic applications into one of three categories, with implications 
for what available evidence has to say about implementation. In addition, this scheme points 
to key evidence sources that can be useful in informed decision-making processes. The 
approach is flexible so that modifications in evidence sources considered, or in how they are 
weighted, can be tailored to meet the needs and address the values of various decision 
makers. In many instances, the classification results convey a general idea of the types of 
research needed to strengthen an existing evidence base or to determine whether a genomic 
application may be productively implemented in the future.
We are using the classification method presented here to populate an evolving online table 
of Genomic Tests and Family History by Levels of Evidence.7 Because the authors are 
involved in public health–driven approaches to genomic implementation, being associated 
with CDC OPHG and/or the National Cancer Institute’s Epidemiology and Genomics 
Research Program, our approach may favor higher evidence thresholds than some would 
propose. Arguments could be made that applying common thresholds to all genomic 
applications is not warranted, or that implementation might be reasonable in some situations 
where no synthesized evidence is likely to be available, such as with some rare disorders. 
Therefore, in deciding which source material to consider “evidence-based,” we have taken a 
some-what liberal view. Ultimately, we acknowledge that this is an area of widespread 
disagreement,46 and others may choose to use our classification method with more or less 
restrictive criteria to account for different priorities and values. Ideally, as synthesized 
evidence continues to accumulate, we might expect to see movement of genomic 
applications away from the Tier 2/Yellow category as clear recommendations for or against 
use become increasingly possible. We are committed to updating the online table on a 
regular basis in order to test this hypothesis. We are also interested in engaging in active 
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dialogue with researchers, policy makers, providers, and test developers on the best 
approaches to collecting and synthesizing evidence for genomic applications in specific 
scenarios. Ultimately, we plan to keep the online table as current as possible, as an ongoing 
service to decision makers in the field. For those whose philosophy on thresholds diverges 
from our approach, the method may still be helpful as a basis for modifications.
The incorporation of evidence derived from US federal sources (e.g., the FDA and the CMS) 
make our classification method and table a somewhat US-centered tool; however, the system 
could easily be modified to meet the specialized needs of other regions, e.g., by substituting 
European Medicines Agency information for FDA data. Our other sources, such as CPGs 
and SRs, have not been limited to those produced in the United States or those based on 
studies of the US population. Our system involves classification based on synthesized 
evidence in the form of SRs and CPGs rather than individual studies. We recognize that 
individual studies (whether clinical, cost focused, modeling based, or others) are crucial for 
the successful implementation of genomic tests; nevertheless, such studies must be 
synthesized into SRs, CPGs, and FDA and CMS decision processes if we are to thoroughly 
understand how they fit into the larger evidence base. Some may object to Tier 1/ Green 
assignment based solely on FDA labeling or CMS coverage decisions because these 
processes do not exactly match the model proposed in the Institute of Medicine report titled 
“Clinical Practice Guidelines We Can Trust.”47 Our rationale for their inclusion is that FDA 
drug labeling and CMS coverage decisions are constructed through defined, deliberative 
processes that use the best available evidence. These sources warrant a similar level of 
consideration as high-quality CPGs (based on SRs) when considering implementation 
strategies. For example, the CMS convenes the Medicare Evidence Development & 
Coverage Advisory Committee as an independent consensus advisory panel that “judges the 
strength of the available evidence and makes recommendations to CMS based on that 
evidence.”48 Moreover, we included CMS and FDA into our tiering scheme where others 
have not as we felt that their regulatory and/or cleavage decisions affect the use of these 
applications.
It might be argued that the Tier 3/Red category contains two qualitatively different subsets 
that should not be combined: (i) applications with recommendations against use and (ii) 
applications for which no synthesized evidence in the form of a CPG, an SR, or CMS or 
FDA information is available. For those who may be interested in conducting additional 
research and incorporating the latest primary study results into decision making, combining 
these subsets in the Tier 3/Red category may not be ideal. We have designed the system 
primarily to benefit an audience of clinicians and public health policy makers interested in 
implementing genomic applications, or not, on the basis of existing synthesized evidence. 
For this audience, Tier 3/ Red applications are expected to be of little interest until some 
supporting synthesized evidence is available.
An acknowledged weakness of our approach is that our classification system is not designed 
to finely differentiate among guidelines on the basis of quality criteria or rigor because not 
all guidelines are created equal.47 In addition, the use of different conventions in evaluating 
evidence and reporting of results among various groups creating SRs and CPGs cannot be 
corrected for in rough classification systems such as ours. More indepth evaluation is 
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possible using instruments such as AGREE II (Appraisal of Guidelines, Research, and 
Evaluation)49,50 and has been done quite effectively to compare genomic guideline 
products51 and methods.52 Instead, we have focused on the intent and general conclusions of 
evidence sources (e.g., informing use, choice, and dose) while providing a rough 
classification involving a few source types (SR, CPG, FDAapproved drug label, and 
Medicare coverage) that are critical for successful implementation. Because of this, our 
classification process can generally be completed and updated more quickly than is possible 
with more detailed instruments.
Another weakness of this and any other summary of evidence is that clinical scenarios may 
not always be specified or well defined in source documents. Even when clinical scenarios 
and recommendations are clear, some degree of interpretation, condensation, and/or 
simplification is necessary when presenting results in tabular form. Critical nuances 
included in FDA-approved drug labels, CMS determinations, CPGs, and SRs may be missed 
during the classification process. Our classification method and evolving table are designed 
to make rough interpretations of the evidence base and point users to the relevant sources of 
evidence, thus saving time spent searching. Nevertheless, decision makers must actually 
read the indicated evidence sources in order to effectively apply their findings.
No horizon-scanning system will be perfectly sensitive, and it is a certainty that we have not 
collected all of the synthesized evidence. There are also enormous challenges associated 
with maintaining a horizon-scanning system and organizing results, due to the rapidly 
evolving evidence base in public health genomics. Even as final revisions to this article are 
being completed, our horizon scans have identified an SR that may have the potential to 
elevate the Tier 3/Red example used in this article to Tier 2/Yellow.53 We will continue 
horizon scanning and classification of results on a continuous basis, acknowledging that 
classifications must be expected to change as evidence develops and evolves. Our system 
has led to an expanding and evolving table of Genomic Tests and Family History by Levels 
of Evidence,7 which we hope will prove useful as a rough guide to stakeholders in the field 
of genomic medicine.
The original impetus for our classification system came from a 3 × 3 risk–benefit policy 
matrix, risk–benefit profile by level of uncertainty, developed by Veenstra et al.54 Although 
an enormously useful tool, we sought to develop an approach that did not require formal 
decision-analytic modeling and resulted in fewer and simpler categories. We hope that our 
simplified approach will prove useful in helping to shape future studies. Ongoing 
translational research can be tailored specifically to each of the tier/color classification 
levels. For applications in Tier 1/Green, research is needed on effective integration of tests 
into practice, whereas evidence on when to implement assumes increased importance in Tier 
2/Yellow scenarios, and accumulating relevant evidence on clinical utility will be needed. A 
key question for Tier 3/Red scenarios is whether, and in which cases, additional research on 
validity and utility might be justified. Although our classification system cannot provide 
detailed answers to these questions, we hope that it will help to identify, organize, and 
prioritize future research while serving decision makers as a heuristic to guide the 
beginnings of more detailed assessments of evidence.
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Note: While this article was in press, new data were published suggesting that no 
improvement in anticoagulation control with warfarin resulted from adding genotype to 
clinical variables in a dosing algorithm (Kimmel et al., N. Engl. J. Med. 19 November 2013, 
Online First). The results of this original study do not immediately affect placement in our 
classification scheme but could be integrated into future guidelines or systematic reviews. 
Rapid progress in the field underscores the need for continuous horizon scanning of the 
evidence.
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Method for classification of genomic applications by levels of evidence for implementation. 
The list is read from top to bottom to determine whether a genomic test meets any of the 
criteria for each of the three color-coded categories or tiers. The listing of criteria should be 
viewed as “OR” statements, so only one criterion needs to be met for categorization. CMS, 
Centers for Medicare & Medicaid Services; FDA, US Food and Drug Administration.
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Table 1
Examples of some evidence sources (i.e., CPGs and SRs) of interest in public health genomics and how their 
corresponding products could be classified for use with our system
Classification References
Guidelines
 ACOG (Practice Bulletin) CPG based on SR 55–58
 ACMG (Practice Guideline) CPG based on SR 36,59
 ASCO (Provisional Clinical Opinion) CPG based on SR 30
 EGAPP (Recommendation Statement) CPG based on SR 32,45,60–65
 NICE (Guidance) CPG based on SR 66
 NCCN CPG based on SR 31
 USPSTF (Recommendation Statement) CPG based on SR 67
 CPIC CPG on dose 34,35,39, 68–72
 PWG CPG on dose 24,25
Systematic reviews
 AHRQ EPC SR 73
 Cochrane SR 74
 BCBSA TEC SR 29
 CMS (Technology Assessment) SR 75
ACMG, American College of Medical Genetics and Genomics; ACOG, American Congress of Obstetricians and Gynecologists; AHRQ EPC, 
Agency for Healthcare Research and Quality Evidence-based Practice Center; ASCO, American Society of Clinical Oncology; BCBSA TEC, Blue 
Cross Blue Shield Association Technology Evaluation Center; CMS, Centers for Medicare & Medicaid Services; CPG, clinical practice guideline; 
CPIC, Clinical Pharmacogenetics Implementation Consortium; EGAPP, Evaluation of Genomic Applications in Practice and Prevention; NCCN, 
National Comprehensive Cancer Network; NICE, National Institute for Health and Clinical Excellence; PWG, Pharmacogenetics Working Group; 
SR, systematic review; USPSTF, US Preventive Services Task Force.
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